Antihypertensive drugs and the sympathetic nervous system.
The sympathetic nervous system (SNS) plays an important role in the regulation of blood pressure homeostasis and cardiac function. Furthermore, the increased SNS activity is a predictor of mortality in patients with hypertension, coronary artery disease and congestive heart failure. Experimental data and a few clinical trials suggest that there are important interactions between the main pressor systems, i.e. the SNS, the renin-angiotensin system and the vascular endothelium with the strongest vasoconstrictor, endothelin. The main methods for the assessment of SNS activity are described. Cardiovascular drugs of different classes interfere differently with the SNS and the other pressor systems. Pure vasodilators including nitrates, alpha-blockers and dihydropyridine (DHP)-calcium channel blockers increase SNS activity. Finally, central sympatholytics and possibly phenylalkylamine-type calcium channel blockers reduce SNS activity. The effects of angiotensin-II receptor antagonists on SNS activity in humans is not clear; experimental data are discussed in this review. There are important interactions between the pressor systems under experimental conditions. Recent studies in humans suggest that an activation of the SNS with pure vasodilators in parallel increases plasma endothelin. It can be assumed that, in cardiovascular diseases with already enhanced SNS activity, drugs which do not increase SNS activity or even lower it are preferable. Whether this reflects in lower mortality needs to be investigated in intervention trials.
Wenzel
R R
RR
Department of Internal Medicine, University Hospital, Essen, Germany.
Bruck
H
H
Noll
G
G
Schäfers
R F
RF
Daul
A E
AE
Philipp
T
T
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000294:innervation; D006801:Humans; D013564:Sympathetic Nervous System / Q000187:drug effects*
D000959:Antihypertensive Agents